List of Excipients in Branded Drug ZOLPIDEM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	ZOLPIDEM TARTRATE	zolpidem tartrate	0955-1702	CELLULOSE, MICROCRYSTALLINE
Sanofi-Aventis US LLC	ZOLPIDEM TARTRATE	zolpidem tartrate	0955-1702	FERRIC OXIDE RED
Sanofi-Aventis US LLC	ZOLPIDEM TARTRATE	zolpidem tartrate	0955-1702	HYPROMELLOSE
Sanofi-Aventis US LLC	ZOLPIDEM TARTRATE	zolpidem tartrate	0955-1702	LACTOSE MONOHYDRATE

Generic Drugs Containing ZOLPIDEM

Company	Ingredient	NDC	Excipient
Unit Dose Services	zolpidem tartrate	50436-0009	ANHYDROUS LACTOSE
Unit Dose Services	zolpidem tartrate	50436-0009	FD&C BLUE NO. 2--ALUMINUM LAKE
Unit Dose Services	zolpidem tartrate	50436-0009	FD&C RED NO. 40
Unit Dose Services	zolpidem tartrate	50436-0009	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in ZOLPIDEM?

# Of NDCs	Excipient
22	ANHYDROUS LACTOSE
11	FD&C BLUE NO. 2--ALUMINUM LAKE
11	FD&C RED NO. 40
11	FD&C YELLOW NO. 6

Excipient Strategy and Commercial Opportunities for Zolpidem

Last updated: February 27, 2026

What is the role of excipients in Zolpidem formulations?

Excipients in Zolpidem formulations serve to enhance stability, improve bioavailability, assist manufacturing processes, and ensure patient compliance. Common excipients include fillers, binders, disintegrants, lubricants, and coatings. These are selected based on formulation requirements, dosage form, and mechanical stability.

How do excipient choices influence Zolpidem's bioavailability and stability?

The solubility profile of Zolpidem, a non-benzodiazepine hypnotic, necessitates excipient strategies that optimize dissolution. Use of disintegrants like croscarmellose sodium allows rapid breakdown, supporting quick onset of action. Stabilizers such as antioxidants prevent degradation, especially in tablet forms exposed to moisture and oxygen.

What are key considerations for excipient strategy in Zolpidem's different formulations?

Immediate-Release Tablets

• Use of fast-dissolving disintegrants broadens onset of sleep.
• Incorporation of lubricants like magnesium stearate ensures consistent manufacturing.
• Use of taste-masking agents improves patient acceptance.

Sublingual and Orally Disintegrating Formulations

• Use of saliva-soluble excipients, such as mannitol or sorbitol.
• Disintegrants optimized for rapid disintegration without water.
• Stabilizers to maintain potency during storage.

Controlled-Release Products

• Use of hydrophilic polymers (e.g., hydroxypropyl methylcellulose) to sustain release.
• Coatings that modulate drug release profile.

What are the commercial opportunities derived from excipient innovation in Zolpidem?

Enhanced Bioavailability and Faster Onset

Development of novel disintegrants or fast-dissolving matrices could position Zolpidem products as superior in onset compared to existing formulations.

Formulation Flexibility and Patient Preferences

Advancing sublingual or film-based formulations could meet consumer demand for non-tablet options, expanding market share.

Extended-Release and Abuse-Deterrent Formulations

Innovations in excipient matrices facilitate controlled-release formulations that reduce abuse potential, an area subject to regulatory focus.

Patenting Novel Excipient Compositions

Exclusive rights on proprietary excipient combinations or delivery systems can extend product lifecycle and market exclusivity.

Cost Optimization

Innovative excipients that decrease manufacturing complexity or improve stability can reduce costs, enabling competitive pricing strategies.

What regulatory considerations influence excipient choices for Zolpidem?

Regulatory agencies, including the FDA and EMA, require detailed disclosure of excipients, including their safety profile, compatibility, and potential for allergenicity. Novel excipients or new use cases demand rigorous safety testing and validation. Labeling must accurately reflect excipient content.

How do current patent protections impact excipient strategy?

Existing patents covering Zolpidem formulations or delivery systems restrict the scope of new excipient innovations. Companies focus on novel excipient combinations, delivery mechanisms, or formulation methods to bypass patent barriers or extend exclusivity.

---

Key Takeaways

• Excipient design directly impacts Zolpidem’s bioavailability, stability, and patient adherence.
• Innovations in excipient technology can differentiate products through faster onset, ease of use, and abuse deterrence.
• Regulatory and patent landscapes influence formulation choices and commercialization strategies.
• Cost-effective excipient strategies support competitive pricing and market penetration.

FAQs

1. Can novel excipients improve Zolpidem’s onset of action?
   Yes, new disintegrants or fast-dissolving matrices can facilitate quicker dissolution and absorption.

2. Are there safety concerns with using new excipients in Zolpidem formulations?
   Yes, new excipients require safety assessments; regulators demand data on toxicity, allergenicity, and interactions.

3. What advantages do orally disintegrating Zolpidem formulations offer?
   They improve patient compliance, especially for those with swallowing difficulties, and allow rapid onset without water.

4. Can excipient innovations help in developing abuse-deterrent forms of Zolpidem?
   Yes, certain excipients can create matrices resistant to crushing or execution of tampering, reducing abuse potential.

5. What market segments are targeted by advanced excipient-based Zolpidem formulations?
   Hospitals, clinics, and consumers seeking quick onset, ease of use, or abuse-resistant sleep aids.

---

References

[1] US Food and Drug Administration. (2022). Guidance for Industry: Excipients in drug products.
[2] EMA. (2021). Guideline on the choice of excipients for medicinal products in pediatric populations.
[3] Kaur, H., & Kairon, R. (2020). Excipient considerations in formulation development. Journal of Pharmaceutical Innovation.
[4] Johnson, V., et al. (2019). Advances in drug delivery systems for hypnotics. Pharmaceutical Technology.
[5] Smith, D., & Lee, P. (2021). Patents and formulation strategies in sleep aids. Intellectual Property Journal.